trending Market Intelligence /marketintelligence/en/news-insights/trending/tsPVlUmg9rWPMogV0b16HQ2 content esgSubNav
In This List

Report: Valeant considers selling eye surgery biz to Carl Zeiss

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Report: Valeant considers selling eye surgery biz to Carl Zeiss

Valeant Pharmaceuticals International Inc. is in discussions to sell its unit Bausch & Lomb's eye surgery products business to Germany's Carl Zeiss Meditec AG, Bloomberg News reported, citing people familiar with the matter.

The assets could be valued about $2 billion in a potential deal, the sources reportedly said.

Negotiations are ongoing, and no decisions have been made. Other bidders could also step up, according to the report.